# Proniras Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proniras

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Website: www.proniras.com
- Total disclosed funding: $4.6M
- Latest round: Series B (Dec 15, 2023)
- Investors on record: 4

## About

Based in Washington, US, and founded by its Chief Scientific Officer, Christopher Toombs, and Accelerator Life Science Partners in 2017, Proniras Corporation, operates as a developer of drugs used for the treatment of neurological conditions. In September 2020, Proniras Corporation received a USD 12.3 million grant from new investors, the National Institute on Drug Abuse and Johnson & Johnson Innovation, with participation from returning investors Alexandria Venture Investments, ARCH Venture Partners, and Eli Lilly & Company, Watson Fund, and WRF Capital.

The company offers AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid), a kainate receptor antagonist for the treatment of seizures and brain injury. Other neurological disorders treated by the company include status epilepticus, pediatric epilepsy, and others.

## Funding rounds

- Series B, Dec 15, 2023, $4.6M — ARCH Venture Partners, WRF Capital, Accelerator Life Science Partners, Watson Fund

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series B
- Accelerator Life Science Partners (https://capitalatlas.ai/funds/accelerator-life-science-partners) — Series B
- Watson Fund (https://capitalatlas.ai/funds/watson-fund) — Series B